Japan’s AGC Makes Agreed €240m Bid For MolMed

Silvio Berlusconi’s Fininvest holds 23% in the cancer-focused biotech

 
• By Sten Stovall

AGC of Japan is offering to buy cell and gene therapy specialist MolMed SPA in a deal worth up to €240m and backed by the biotech’s biggest shareholder, Silvio Berlusconi’s Fininvest.

M&A
AGC wants to catch clinical-stage Italian biotech MolMed • Source: Shutterstock

More from Business

More from Scrip